MAPT and Alzheimer disease: Despite the differences in clinical presentation and in underlying causes for Alzheimer’s disease development, both groups show similar disease progression, cognitive decline rate and CSF Aβ42 and total tau biomarker patterns, reflecting a common cascade of events leading to the emergence of symptomatic Alzheimer’s disease.